Abstract
Background
Transient ischemic attack (TIA) is an important predictor for a pending stroke. Guidelines recommend a workup for TIA-patients similar to that of stroke patients, including an assessment of the extra- and intracranial arteries for vascular pathologies with direct therapeutic implications via computed tomography angiography (CTA). Aim of our study was a systematic analysis of TIA-patients receiving early CTA-imaging and to evaluate the predictive value of TIA-scores and clinical characteristics for ipsilateral vascular pathologies and the need of an invasive treatment.
Methods
We analysed clinical and imaging data from TIA patients being admitted to a tertiary university hospital between September 2015 and March 2018. Following subgroups were identified: 1) no- or low-grade vascular pathology 2) ipsilateral high-risk vascular pathology and 3) high-risk findings that needed invasive, surgical or interventional treatment. We investigated established TIA-scores (ABCD2-, the ABCD3- and the SPI-II score) and various clinical characteristics as predictive factors for ipsilateral vascular pathologies and the need for invasive treatment.
Results
Of 812 patients, 531 (65.4%) underwent initial CTA in the emergency department. In 121 (22.8%) patients, ipsilateral vascular pathologies were identified, of which 36 (6.7%) needed invasive treatment. The ABCD2-, ABCD3- and SPI-II-scores were not predictive for ipsilateral vascular pathologies or the need for invasive treatment. We identified male sex (OR 1.579, 95%CI 1.049–2.377, p = 0.029), a short duration of symptoms (OR 0.692, 95% CI 0.542–0.884, p = 0.003), arterial hypertension (OR 1.718, 95%CI 0.951–3.104, p = 0.073) and coronary heart disease (OR 1.916, 95%CI 1.184–3.101, p = 0.008) as predictors for ipsilateral vascular pathologies. As predictors for the need of invasive treatment, a short duration of symptoms (OR 0.565, 95%CI 0.378–0.846, p = 0.006), arterial hypertension (OR 2.612, 95%OR 0.895–7.621, p = 0.079) and hyperlipidaemia (OR 5.681, 95%CI 0.766–42.117, p = 0.089) as well as the absence of atrial fibrillation (OR 0.274, OR 0.082–0.917, p = 0.036) were identified.
Conclusion
More than every fifth TIA-patient had relevant vascular findings revealed by acute CTA. TIA-scores were not predictive for these findings. Patients with a short duration of symptoms and a vascular risk profile including coronary heart disease, arterial hypertension and hyperlipidaemia most likely might benefit from early CTA to streamline further diagnostics and therapy.
Supplementary Information
The online version contains supplementary material available at 10.1186/s12883-021-02523-y.
Background
TIA is a well-known predictor for a manifest ischemic stroke with an incidence over 10% within 3 months after the index TIA. Nearly half of ischemic strokes occur during the first 2 days after the index TIA [1]. Scores like the ABCD2-Score [2], the ABCD3-Score [3] and the Stroke Prognosis Instrument-II (SPI-II) [4] have been developed to quantify the risk of a pending stroke after TIA. To reduce the risk for a pending ischemic stroke following a TIA, it is important to perform a full diagnostic workup to identify common aetiologic causes like ipsilateral vascular stenosis or occlusion. With a consequent workup and early treatment in specialised stroke centers, the risk for recurring strokes can be reduced below 3.5% after 90 days [5, 6].
Patients with TIA, owing to intrinsic thrombolytic mechanisms and cerebral collateral status, can present with transient ischemic symptoms despite severe proximal stenosis, dissection of brain supplying vessels, acute occlusion of pre-existing stenosis or as a result of an acute embolic occlusion of large cerebral vessels [7]. In this respect, current guidelines recommend managing TIA-patients the same way as patients with a manifest stroke in the emergency department, which include that a computed tomography angiography (CTA) of the brain supplying arteries should be considered [8–10]. Macroangiopathic causes like arterial stenosis or occlusion account for around 23% of all TIA-cases, which reliably can be detected using CTA [11, 12]. Hereby, vascular findings in the CTA allow preventive measures and may have a direct impact on the acute treatment of the TIA-patient e. g. for a hemodynamically relevant dissection, intravascular thrombi, or an acute large vessel occlusion. Only the targeted diagnosis of one of those pathologies justifies the performance of a CTA, whose possible side effects include the risk of nephrotoxicity (in 2% of cases) and the risk of an allergic reaction to contrast agent (in 0.01% of cases) as well as additional radiation exposure which is two times higher than that of a native CT-scan [13–15].
The aim of our study was to perform a systematic evaluation of the role of CTA imaging in the acute setting of TIA, to evaluate which subgroups of TIA-patients benefit from initial imaging with CTA and to investigate the predictive value of TIA-scores regarding ipsilateral vascular pathologies.
Methods
Patient population and study design
In this retrospective study, clinical and imaging data was collected from patients with the admission diagnosis TIA, who were treated in a tertiary university hospital between September 2015 and March 2018. From all identified patients with TIA as their admission diagnosis, a total number of 222 patients were excluded for the following reasons (see Fig. 1): 74 patients had insufficient data (minimal dataset not available), 50 patients had a change of diagnosis during in hospital stay (e.g. TIA-mimics like intoxication or hypoglycaemia), 55 patients were follow-up cases in our vascular outpatient clinic and not admitted via the emergency department, 22 patients refused treatment during in-patient stay and did not receive full workup and 21 patients presented with pyramidal tract signs (like Babiski’s-, Gordon’s- or Oppenheim’s sign), which are more likely to indicate an ischemic stroke rather than a TIA.
The remaining 812 TIA-patients were categorised into three subgroups: 1) no or low-grade vascular pathology, 2) high-grade, ipsilateral vascular pathology (highly likely to have caused the TIA) and 3) patients with the need for invasive treatment (e.g. surgically or interventionally). A low-grade vascular pathology was considered, if it occluded less than 50% of the vessel, according to the North American Symptomatic Carotid Endarterectomy Trial (NASCET) [16]. Vascular pathologies with a stenosis over 50% (NASCET) were considered as high-grade. Patients were categorized in the second group (ipsilateral vascular pathology), if high-risk pathologies like high-grade stenosis (> 50% NASCET), vascular dissection, complete occlusions or intraarterial thrombi ipsilateral to the affected territory were diagnosed. All vascular pathologies were either diagnosed by CTA in the emergency department in combination with consecutive neurovascular ultrasound or by neurovascular ultrasound alone. Neurovascular ultrasound of all accessible cerebral vessels was performed by experienced neurologists and CTA were reviewed by experienced neuroradiologists. Patients receiving invasive treatment like intravenous thrombolysis (IVT), mechanical thrombectomy (MT), surgical (carotid endarterectomy (CEA)) or interventional treatment (e.g. carotid artery stenting (CAS)) were assigned to group 3.
Data was obtained from the emergency medical service documentation, the clinics digital patient documentation system ixserv (ixmid Software Technologie GmbH) and the intensive care information system IntelliSpace Critical Care and Anaesthesia (Philips). The collected data included baseline characteristics like age and sex, initial assessment, kind of symptoms, symptom duration and National Institute of Health Stroke Scale (NIHSS), lab results, patient’s medical history and pre-medication. The results of stroke-imaging and neurovascular ultrasound were included. Finally, we documented if the patients received IVT, MT, CEA, CAS or carotid percutaneous transluminal angioplasty without stenting (PTA only). From all available data we calculated every patients ABCD2-score, ABCD3-score and Stroke Prognosis Instrument II [2–4]. The ABCD2-score includes the items age, blood pressure, neurologic symptoms, duration of symptoms and diabetes mellitus. The ABCD3-score adds the item TIA within the last 7 days. The SPI-II focusses more on pre-existing conditions like heart failure, coronary heart disease, history of stroke and diabetes. It is completed by the items age, blood pressure and duration of symptoms longer than 24 h.
Statistical analysis
Statistical analysis was performed using SPSS 21 (IBM SPSS Statistics, Armonk, NY, USA). Baseline characteristics were described using frequencies, means and median with standard deviation and interquartile range, as applicable. Predefined groups (group 1: no or low-grade vascular pathology, group 2: high-grade, ipsilateral vascular pathology and group 3: need for invasive treatment) were compared using T-tests, Wilcoxon-Mann-Whitney tests and χ2 test, as appropriate. Predictors for ipsilateral vascular pathologies were included in uni- and multivariate logistic regression models. To create predictive models for the endpoints ‘ipsilateral vascular pathology’ and ‘need for invasive treatment’ we selected predictors, if 1) they were clinically plausible, 2) they were known at baseline (e.g. from history-taking or clinical examination and 3) they did not cause multicollinearity within the model. For the multivariate, binary logistic regression analysis, the backward selection function with a removal cut-off from the model of p < 0.1 has been used to identify the factors with the highest predictive value. To evaluate the predictive value of the multivariate logistic regression models and the TIA scores, Area Under the Receiver Operator Curves (AUROC) and confidence intervals (CIs) were calculated.
Results
In total, 1034 patients with the admission diagnosis ‘TIA’ were screened, of which 812 were ultimately included in the study. Of these 812 patients, 531 (65.4%) received immediate CTA in the emergency department. Baseline characteristics are given in Table 1 and the symptoms present on first examination are described in supplementary Table 1.
Table 1.
No ipsilateral vascular pathology (n = 691) | Ipsilateral vascular pathology (n = 121) | P-value | No invasive treatment (n = 776) | Invasive treatment (n = 36) | P-value | |
---|---|---|---|---|---|---|
Demographic data | ||||||
Age, years ± SD | 71 ± 14 | 71 ± 13 | 0.760 | 71 ± 14 | 68 ± 11 | 0.165 |
Sex (male, %) | 365 (52.8) | 78 (64.5) | 0.018 | 420 (54.1) | 23 (63.9) | 0.305 |
Clinical presentation | ||||||
Systolic blood pressure (median mmHg, IQR) | 150 (135–168) | 148 (131–168) | 0.789 | 150 (132–169) | 149 (136–154) | 0.495 |
Diastolic blood pressure (median mmHg, IQR) | 80 (70–90) | 80 (66–90) | 0.078 | 80 (70–90) | 80 (65–90) | 0.416 |
NIHSS (median, IQR) | 0 (0–1) | 0 (0–1) | 0.270 | 0 (0–1) | 0 (0–0.75) | 0.097 |
Duration of symptoms | 0.020 | 0.012 | ||||
< 10 min | 107 (15.5) | 31 (25.6) | 126 (16.2) | 12 (33.3) | ||
< 60 min | 163 (23.6) | 28 (23.1) | 181 (23.3) | 10 (27.8) | ||
> 60 min | 421 (60.9) | 62 (51.2) | 469 (60.4) | 14 (38.9) | ||
Co-morbidities | ||||||
Arterial hypertension (n, %) | 551 (79.7) | 106 (87.6) | 0.042 | 625 (80.5) | 32 (88.9) | 0.213 |
Hyperlipidaemia (n, %) | 590 (85.4) | 108 (89.3) | 0.258 | 663 (85.4) | 35 (97.2) | 0.047 |
Atrial fibrillation (n, %) | 148 (21.4) | 29 (24.0) | 0.531 | 174 (22.4) | 3 (8.3) | 0.045 |
Diabetes mellitus (n, %) | 166 (24) | 29 (24) | 0.989 | 187 (24.1) | 8 (22.2) | 0.797 |
Obesity (n, %) | 119 (17.2) | 26 (21.5) | 0.258 | 134 (17.3) | 11 (30.6) | 0.042 |
Coronary heart disease (n, %) | 97 (14) | 31 (25.6) | 0.001 | 121 (15.6) | 7 (19.4) | 0.535 |
Heart failure (n, %) | 91 (13.2) | 18 (14.9) | 0.611 | 104 (13.4) | 5 (13.9) | 0.933 |
History of myocardial infarction (n, %) | 48 (6.9) | 20 (16.5) | < 0.001 | 6.4 (8.2) | 4 (11.1) | 0.544 |
Aortic valve stenosis (n, %) | 38 (5.5) | 8 (6.6) | 0.625 | 44 (5.7) | 2 (5.6) | 0.977 |
Chronic kidney disease (n, %) | 104 (15.1) | 22 (18.2) | 0.380 | 120 (15.5) | 6 (16.7) | 0.846 |
PFO (n, %) | 119 (17.2) | 15 (12.4) | 0.187 | 130 (16.8) | 4 (11.1) | 0.373 |
PFO + atrial aneurysm (n, %) | 23 (3.3) | 0 (0) | 0.042 | 23 (3) | 0 (0) | 0.295 |
Pulmonal embolism (n, %) | 8 (1.2) | 2 (1.7) | 0.649 | 23 (3) | 0 (0) | 0.295 |
History of cancer (n, %) | 74 (10.7) | 13 (10.7) | 0.991 | 84 (10.8) | 3 (8.3) | 0.637 |
History of ischemic stroke (n, %) | 137 (19.8) | 33 (27.3) | 0.063 | 162 (20.9) | 8 (22.2) | 0.846 |
TIA within the last seven days (n, %) | 85 (12.3) | 20 (16.5) | 0.201 | 96 (12.4) | 9 (25.0) | 0.027 |
Medication | ||||||
Antiplatelet medication (n, %) | 250 (36.2) | 70 (57.9) | < 0.001 | 299 (38.5) | 21 (58.3) | 0.017 |
Dual antiplatelet medication (n, %) | 15 (2.2) | 10 (8.3) | < 0.001 | 24 (3.1) | 1 (2.8) | 0.915 |
NOAK (n, %) | 50 (7.2) | 8 (6.6) | 0.806 | 56 (7.2) | 2 (5.6) | 0.705 |
Marcumar (n %) | 66 (9.6) | 14 (11.6) | 0.429 | 78 (10.1) | 2 (5.6) | 0.376 |
Antihypertensive medication (n, %) | 508 (73.5) | 100 (82.6) | 0.033 | 578 (74.5) | 30 (83.3) | 0.231 |
Antihyperlipidemic medication (n, %) | 246 (35.6) | 69 (57) | < 0.001 | 295 (38) | 20 (55.6) | 0.035 |
SD Standard deviation, IQR Interquartile range, NIHSS National Institute of Health Stroke Scale, PFO Persistent foramen ovale, TIA Transient ischemic attack, NOAK New oral anticoagulant
TIA-patients with ipsilateral vascular pathologies were more likely to be male (64.5% vs. 52.8%, p = 0.018), to have a history of arterial hypertension (87.6 vs. 79.7, p = 0.042), coronary heart disease (25.6% vs. 14%, p = 0.001), myocardial infarction (16.5% vs. 6.9%, p < 0.001) and ischemic stroke (27.3% vs. 19.8%, p = 0.063). Patients with the need for invasive treatment were more likely to have hyperlipidaemia (97.2% vs. 85.4%, p = 0.047), to be obese (30.6% vs. 17.3%, p = 0.042) and to have had a TIA within 7 days prior to the index TIA (25% vs. 12.4%, p = 0.027) as well as less likely to have atrial fibrillation (8.3% vs 22.4%, p = 0.045). Both patients with ipsilateral vascular pathologies and patients with the need for invasive treatment had a lower duration of TIA-symptoms (with highest differences in the group of patients with a symptom duration of < 10 min) and were more likely to be on antiplatelet- and lipid lowering medication. There were no significant differences concerning presenting symptoms between the groups with- and without ipsilateral vascular pathologies, while patients with the need for invasive treatment were more likely to present with hemiparesis (52.8% vs. 34.7, p = 0.026) and amaurosis fugax (19.4% vs. 9.5%, p = 0.052) and were less likely to present with dysarthria (8.3% vs. 22.9%, p = 0.040).
Using the imaging data of the 531 patients receiving a CTA in the emergency department, we found that 121 (22.8%) patients showed a high-grade ipsilateral arterial pathology: 91 (17.1%) were found with high-grade, ipsilateral arterial stenosis, 20 (3.8%) patients with a haemodynamic relevant, ipsilateral arterial occlusion, 6 (1.1%) patients with an arterial dissection and 2 (0.4%) patients with instable intraarterial thrombi. Of the 121 patients with high-grade ipsilateral arterial pathology, 36 (6.8%) received invasive treatment: 19 (3.6%) patients received CEA, 9 (1.7%) received CAS, 4 (0,7%) patients received PTA without stenting, 3 (0.6%) patients received an IVT and one (0.2%) patient received subclavian-carotid bypass surgery. None of the patients received an MT based on the acute CTA. More than half of the interventions were performed within 1 week after the CTA and all invasive treatments were performed during the in-patient stay after the index TIA within a maximum period of 2 weeks. There was no immediate intervention after the CTA, not taking IVTs into consideration. In contrast, of all 281 patients without early CTA, 3 (1.1%) patients were diagnosed with high-grade ipsilateral vascular pathology (stenosis) via neurovascular ultrasound during in-hospital stay; one (0.4%) patient underwent CEA.
Using the ABCD2-, ABCD3- and the SPI-II-Score, we found no significant difference between patients with- and without ipsilateral vascular pathologies or the need for invasive treatment (Table 2). These TIA-scores sowed no predictive value for both endpoints in the univariate- and multivariate logistic regression analysis corrected for possible confounders (supplementary Table 2).
Table 2.
TIA Scores | No ipsilateral vascular pathology (n = 691) | Ipsilateral vascular pathology (n = 121) | P-value | No invasive treatment (n = 776) | Invasive treatment (n = 36) | P-Value |
---|---|---|---|---|---|---|
ABCD2-Score (median, IQR) | 4 (3–5) | 4 (3–5) | 0.478 | 4 (3–5) | 4 (3–5) | 0.941 |
ABCD3-Score (median, IQR) | 4 (3–6) | 5 (3–6) | 0.757 | 4 (3–6) | 5 (3.25–6) | 0.287 |
SPI-II (median, IQR) | 3 (0–5) | 3 (1–6) | 0.142 | 3 (1–5) | 2.5 (0.25–5) | 0.703 |
TIA Transient ischemic attack, IQR Interquartile range, SPI-II Stroke prognosis instrument
As shown in Table 3, multivariate logistic regression models were created to identify predictive factors for ipsilateral vascular pathologies and the need for invasive treatment using demographic and anamnestic data alone (see Tables 1 and 2)- and in combination with presenting symptoms (see supplementary Table 1). For ipsilateral vascular pathology, male sex (OR 1.579, 95%CI 1.049–2.377, p = 0.029), a short duration of symptoms (OR 0.692, 95%CI 0.542–0.884, p = 0.003), arterial hypertension (OR 1.718, 95%CI 0.951–3.104, p = 0.073) and coronary heart disease (OR 1.916, 95%CI 1.184–3.101, p = 0.008) were identified as predictors. Including also presenting symptoms in the analysis, the presence of vertigo remained as an additional significant predictor (OR 1.587, 95%CI 1.001–2.516, p = 0.049). Predictive factors for the need for an invasive treatment were a short duration of symptoms (OR 0.565, 95%CI 0.378–0.846, p = 0.006), arterial hypertension (OR 2.612, 95%CI 0.895–7.621, p = 0.079), hyperlipidaemia (OR 5.681, 95%CI 0.766–42.117, p = 0.089) and the absence of atrial fibrillation (OR 0.274, 95%CI 0.082–0.917, p = 0.036). Including presenting symptoms, hemiparesis as one presenting symptom (OR 2.659, 95%CI, 1.325–5.337, p = 0.006) and the absence of dysarthria (OR 0.321, 95%CI 0.096–1.078, p = 0.066) remained in the predictive model.
Table 3.
Regression coefficient | OR | 95%CI | P-value | |
---|---|---|---|---|
Ipsilateral vascular pathology (model excluding presenting symptoms) | ||||
Sex, male | 0.457 | 1.579 | 1.049–2.377 | 0.029 |
Duration of Symptoms | −0.368 | 0.692 | 0.542–0.884 | 0.003 |
Arterial Hypertension | 0.541 | 1.718 | 0.951–3.104 | 0.073 |
Coronary heart disease | 0.650 | 1.916 | 1.184–3.101 | 0.008 |
Intercept | −1.723 | 0.179 | < 0.001 | |
Ipsilateral vascular pathology (model including presenting symptoms) | ||||
Sex, male | 0.433 | 1.542 | 1.023–2.326 | 0.039 |
Duration of Symptoms | −0.402 | 0.669 | 0.522–0.857 | 0.001 |
Arterial Hypertension | 0.561 | 1.753 | 0.968–3.173 | 0.064 |
Coronary heart disease | 0.662 | 1.939 | 1.196–3.145 | 0.007 |
Vertigo | 0.462 | 1.587 | 1.001–2.516 | 0.049 |
Intercept | −1.751 | 0.174 | < 0.001 | |
Need for invasive treatment (model excluding presenting symptoms) | ||||
Duration of symptoms | −0.570 | 0.565 | 0.378–0.846 | 0.006 |
Arterial Hypertension | 0.960 | 2.612 | 0.895–7.621 | 0.079 |
Hyperlipidaemia | 1.737 | 5.681 | 0.766–42.117 | 0.089 |
Atrial fibrillation | −1.293 | 0.274 | 0.082–0.917 | 0.036 |
Intercept | −4.023 | 0.018 | 0.001 | |
Need for invasive treatment (model including presenting symptoms) | ||||
Duration of symptoms | −0.600 | 0.549 | 0.363–0.892 | 0.004 |
Arterial Hypertension | 0.971 | 2.639 | 0.896–7.774 | 0.078 |
Hyperlipidaemia | 1.761 | 5.821 | 0.781–43.363 | 0.086 |
Atrial fibrillation | −1.323 | 0.266 | 0.079–0.901 | 0.033 |
Dysarthria | −1.135 | 0.321 | 0.096–1.078 | 0.066 |
Hemiparesis | 0.978 | 2.659 | 1.325–5.337 | 0.006 |
Intercept | −4.243 | 0.014 | < 0.001 |
OR Odds ratio, CI Confidence interval
Predictive values for multivariate models in Table 3 for the endpoint ‘ipsilateral vascular pathology’ (model excluding presenting symptoms: AUROC, 0.63; 95%CI, 0.577–0.686, p < 0.001; model including presenting symptoms: AUROC, 0.646; 95%CI 0.592–0.699, p < 0.001) and the endpoint ‘need for invasive treatment’ (model excluding presenting symptoms: AUROC, 0.722; 95%CI 0.633–0.811, p < 0.001; model including presenting symptoms: AUROC, 0.765, 95%CI, 0.683–0.846) were moderate. All TIA scores were not predictive for the endpoints ‘ipsilateral vascular pathology’ and ‘need for invasive treatment’ alone (AUROC < 0.6, p = n.s.) and performance was not improved after forcing the TIA scores in the clinical prediction models (data not shown).
Discussion
In our study, we found high-grade, ipsilateral arterial pathologies in around 23% of all patients with TIA diagnosed by acute CTA and a need for invasive treatment in around 7% of cases. These numbers indicate that CTA in the acute setting of TIA is justified in selected patient subgroups. As predictors, we identified cardiovascular disease and a short period of symptoms which might be useful for patient selection. In contrast, established TIA-scores turned out to be not predictive for high-grade vascular pathologies.
TIA and ischemic stroke, both indistinguishable in the acute setting in most cases, require vascular imaging. Besides CTA, there are other imaging methods to be considered for neurovascular status evaluation like magnetic resonance imaging and neurovascular ultrasound. Neurovascular ultrasound of the arteries supplying the brain has a high spatial resolution and can detect atherosclerotic changes as well as other vascular pathologies with high accuracy. However, it is limited by investigator dependency and availability. Neurovascular ultrasound in the acute setting can also result in treatment delays due to longer investigation times and patient factors like incompliance, anatomical problems like insufficient transtemporal doppler window and the fact that distal intracranial arteries as well as distal parts of the internal carotid arteries cannot be visualized [17]. Therefore, neurovascular ultrasound is not performed on a regular basis in the acute phase of ischemic stroke if fast and targeted therapy like IVT and EVT is available [18]. Magnetic resonance imaging (MRI) is one of the most important methods to assess the brain tissue. However, it has been shown that CT combined with CTA provides a comparable quality to diffusion-weighted MRI in stroke patients [19]. Considering that MRI resources are more limited compared to CT, which is available 24/7 in all stroke centres, is significantly faster and has a high sensitivity for the diagnosis of vessel occlusions and haemorrhages, CT imaging is the technology of choice in the acute setting of stroke [20]. Considering all advantages and disadvantages of the stroke imaging modalities, it should be noted that vascular imaging should be performed as soon as possible in all suspected TIA and stroke cases.
The evaluated ABCD2-, ABCD3-score and SPI-II, which all stratify the risk for ischemic stroke after TIA, were not predictive for ipsilateral vascular pathologies or the need for invasive treatment in our study. This observation corresponds to findings from Lou et al. investigating the ABCD2-Score as a possible predictor for an interventional treatment. In their study, which included 121 patients with TIA, they found that the ABCD2-Score was equally distributed in patients no matter whether they received an intervention or not [21]. Reasons for the missing predictive value of these TIA-scores might be that they have been designed to predict recurrence rates of TIA or ischemic stroke rather than to predict the underlying aetiology, which include various mechanisms. Many factors incorporated in these scores (admission blood pressure, age, diabetes mellitus and heart failure) were equally distributed in our cohort, raising the suspicion that these factors are likely to be usable to quantify instability (risk of recurrence) of the underlying pathology, but are not predictive for the underlying pathology itself. Also, most items are related to the neurologic symptoms presented at admission. As the most important predictors for vascular disease like chronic arterial hypertension, hyperlipidaemia, smoking and other vascular diseases are not considered in these scores, this might explain the lack of their predictive value [22, 23].
Our results suggest that it might be beneficial to take a certain risk profile into account when deciding whether to perform a CTA in the acute setting of TIA or not. Patients with coronary heart disease have a high risk for macroangiopathic vessel disease which again is highly associated with TIA; our data suggests that these patients – especially if combined with a male sex and arterial hypertension - should receive CTA in the acute setting of TIA to diagnose high-risk vascular pathologies and to initiate targeted therapy. CTA in this case could contribute to a gain of time to diagnosis and could contribute to reduce the risk for TIA recurrence or a manifest ischemic stroke. For example, patients with symptomatic high-grade stenosis and poor vascular flow and collateralisation status are at high risk of early disabling stroke [24]. A CTA could reveal the stenosis as well as collateral status and therefore guide targeted blood pressure therapy. In addition, a study by Hause et al. identified de novo dual antiplatelet therapy as a significant predictor for spontaneous recanalization in patients with symptomatic acute extracranial carotid occlusion [25]. Other studies revealed that dual antiplatelet therapy after TIA and minor stroke reduces the risk of recurrent stroke [26–28], which led to the initiation of early dual antiplatelet therapy in current practice. Therefore, the early, targeted initiation of dual antiplatelet therapy can be reassured in patients with an early diagnosis of high-grade, arterial pathologies of the brain supplying vessels in the context of TIA. In this patient group, this early secondary prophylaxis strategy might have the highest impact (e.g. in contrast to in patients with undiagnosed, intermittent atrial fibrillation). However, taking all these findings into account, to date there is no study demonstrating a benefit concerning functional outcome measures in patient with- or without early imaging with CTA. Whether the performance of CTA in the acute setting of TIA translates into outcome improvements must be addressed by future prospective studies.
A short duration of symptoms in TIA-patients is likely to be associated with macroangiopathic arterial disease of brain supplying arteries and can be found in most patients with carotid artery stenosis. A prototype of a short-lasting neurologic deficit associated with carotid artery stenosis is the amaurosis fugax, a special form of TIA [29, 30]. Already in the seventies, Pessin et al. and Harrison et al. found that TIA-patients with symptoms lasting less than 1 h were more likely to have a carotid artery stenosis and should get an angiography [31, 32]. These results are in line with our finding, that a short duration of symptoms increases the odds to diagnose a high-grade, ipsilateral vascular pathology in patients with TIA. In contrast, cardiac emboli are more likely to cause permanent and more severe focal neurological deficits [33–35]. The difference in duration of symptoms caused by arterial or cardiac emboli could be explained by a difference in spontaneous revascularization due to a variation of composition and size of the thrombi [32, 36, 37]. Another point to consider is the collateralisation status in patients with arterial emboli caused by vessel stenosis compared to cardiac embolization with no associated vessel stenosis. Arterial stenosis formation take month to years to develop and induces intracranial collateralization, which is not present in cardiac embolization leading to an acute haemodynamic deficit of brain perfusion. This fact could explain the short symptom duration in patients with arterial stenosis, where cerebral hemodynamics can adapt in a few seconds [38]. Therefore, short duration of symptoms should not be discarded as trivial by the clinician but raise the suspicion of macroangiopathic disease with associated findings in CTA. Concerning the timely development of symptoms, TIA “in crescendo” was previously shown to significantly correlate with large artery atherosclerosis as the origin of TIA [39]. However, this association couldn’t be investigated in our study, as the dynamic and evolution of symptoms were not recorded by the treating physicians.
In addition, our analysis showed that vertigo as presenting symptom of TIA patients predicts relevant vascular pathologies. Although vertigo is a frequent and unspecific symptom in the emergency department, it could be caused by hemodynamic disturbances and impaired cerebral perfusion in patients with stenosis and occlusions of brain supplying arteries. As with a short duration of presenting symptoms, based on our finding the clinician should also pay attention to this unspecific symptom, since it could increase the odds to diagnose relevant vascular findings on CTA in TIA patients.
A strength of our study is the high number of included patients as well as the use of “real word” data from a large volume, tertiary stroke centre. Limitations include the monocentric, retrospective design of the study. Moreover, a selection bias must be considered, as only 66% of patients with TIA received a CTA in the emergency department. The reason for the decision to perform or not to perform a CTA in the acute setting could be influenced by multiple factors like preference of the consultant neurologist in charge, patient factors like kidney disease and medical history of the patient. Another weakness is the lack of MRI data. Therefore, we must assume that our patient population is a mixture of TIA and minor-stroke patients. If more MRI data had been available, the results of our study might be different. However, our data represents everyday clinical praxis and the frequent lack of MRI imaging in even large stroke centres [40].
The results of our study warrant further prospective research on important information like the follow up on patients and how CTA influences their therapy and outcome compared to other imaging methods like neurovascular ultrasound. Further prospective studies could also be used to develop risk scores defining cut-off values to identify patients likely to benefit from acute imaging with CTA.
Conclusion
In this study, CTA revealed high-grade ipsilateral pathology in more than every fifth patient with TIA and therefore represents an important diagnostic tool in initial workup. History of coronary heart disease, a short duration of symptoms and vertigo as presenting symptom may be useful in triaging TIA patients for acute CTA. Our findings justify performing a prospective, randomized trial that compares patients who receive early neurovascular ultrasound, early CTA and usual care. We want to emphasise that every patient presenting with a persistent acute focal neurologic deficit in emergency department needs immediate vascular imaging, as at this stage a TIA is indistinguishable from a stroke favouring CT-based imaging.
Supplementary Information
Acknowledgements
Not applicable.
Abbreviations
- CAS
Carotid artery stenting
- CEA
Carotid endarterectomy
- CTA
Computed tomography angiography
- IVT
Intravenous thrombolysis
- MRI
Magnetic resonance imaging
- MT
Mechanical thrombectomy
- PTA
Percutaneous transluminal angioplasty
- SPI-II
Stroke prognosis instrument II
- TIA
Transient ischaemic attack
Authors’ contributions
GH, IM, MB, MP and JL conceived the study. GH and IM were involved in the protocol development. GH and IM wrote the first draft of the manuscript and qualify equally for the first authorship. IM conducted the statistical analysis. All authors provided continuous evaluation during the study process, reviewed and edited the manuscript and approved the final version of the manuscript.
Funding
Open Access funding enabled and organized by Projekt DEAL. The authors received no financial support for the research, authorship, and/or publication of this article.
Availability of data and materials
All data generated or analysed during this study are included in this published article.
Declarations
Ethics approval and consent to participate
The ethics commission of the University Medicine Göttingen waived an ethical approval. Written informed consent was obtained from the patient(s) for their participation in this study.
Consent for publication
Not applicable.
Competing interests
The Authors declare that there is no conflict of interests.
Footnotes
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Ilko L. Maier and Gerrit U. Herpertz contributed equally to this work.
Contributor Information
Ilko L. Maier, Email: ilko.maier@med.uni-goettingen.de
Gerrit U. Herpertz, Email: gerrit.herpertz@klinikum-bremerhaven.de
Mathias Bähr, Email: mbaehr@gwdg.de.
Marios-Nikos Psychogios, Email: marios.psychogios@usb.ch.
Jan Liman, Email: jliman@gwdg.de.
References
- 1.Easton JD, Saver JL, Albers GW, Alberts MJ, Chaturvedi S, Feldmann E, et al. Definition and evaluation of transient ischemic attack: a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association Stroke Council; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; and the Interdisciplinary Council on Peripheral Vascular Disease. The American Academy of Neurology affirms the value of this statement as an educational tool for neurologists. Stroke. 2009;40:2276–2293. doi: 10.1161/STROKEAHA.108.192218. [DOI] [PubMed] [Google Scholar]
- 2.Fothergill A, Christianson TJH, Brown RD, Rabinstein AA. Validation and refinement of the ABCD2 score: a population-based analysis. Stroke. 2009;40:2669–2673. doi: 10.1161/STROKEAHA.109.553446. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Merwick Á, Albers GW, Amarenco P, Arsava EM, Ay H, Calvet D, et al. Addition of brain and carotid imaging to the ABCD2 score to identify patients at early risk of stroke after transient ischaemic attack: a multicentre observational study. Lancet Neurol. 2010;9:1060–1069. doi: 10.1016/S1474-4422(10)70240-4. [DOI] [PubMed] [Google Scholar]
- 4.Kernan WN, Viscoli CM, Brass LM, Makuch RW, Sarrel PM, Roberts RS, et al. The stroke prognosis instrument II (SPI-II): a clinical prediction instrument for patients with transient ischemia and nondisabling ischemic stroke. Stroke. 2000;31:456–462. doi: 10.1161/01.STR.31.2.456. [DOI] [PubMed] [Google Scholar]
- 5.Valls J, Peiro-Chamarro M, Cambray S, Molina-Seguin J, Benabdelhak I, Purroy F. A current estimation of the early risk of stroke after transient ischemic attack: a systematic review and Meta-analysis of recent intervention studies. Cerebrovasc Dis. 2017;43:90–98. doi: 10.1159/000452978. [DOI] [PubMed] [Google Scholar]
- 6.Lavallée PC, Meseguer E, Abboud H, Cabrejo L, Olivot J-M, Simon O, et al. A transient ischaemic attack clinic with round-the-clock access (SOS-TIA): feasibility and effects. Lancet Neurol. 2007;6:953–960. doi: 10.1016/S1474-4422(07)70248-X. [DOI] [PubMed] [Google Scholar]
- 7.Nadarajan V, Perry RJ, Johnson J, Werring DJ. Transient ischaemic attacks: mimics and chameleons. Pract Neurol. 2014;14:23–31. doi: 10.1136/practneurol-2013-000782. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, et al. Guidelines for the early Management of Patients with Acute Ischemic Stroke: 2019 update to the 2018 guidelines for the early Management of Acute Ischemic Stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2019;50:e344–e418. doi: 10.1161/STR.0000000000000211. [DOI] [PubMed] [Google Scholar]
- 9.Ringleb P, Köhrmann M, Jansen O, et al. Akuttherapie des ischämischen Schlaganfalls, S2e-Leitlinie, 2021, in: Deutsche Gesellschaft für Neurologie (Hrsg.), Leitlinien für Diagnostik und Therapie in der Neurologie. Online: https://www.dgn.org/leitlinien. Accessed 21 Oct 2021.
- 10.Ringleb P, Hamann GF, Röther J, et al.: Akuttherapie des ischämischen Schlaganfalls – Ergänzung 2015 – Rekanalisierende Therapie – Leitlinien für Diagnostik und Therapie in der Neurologie, in: Deutsche Gesellschaft für Neurologie (Hrsg.), Leitlinien für Diagnostik und Therapie in der Neurologie. Online: https://www.dgn.org/leitlinien. Accessed 21 Oct 2021.
- 11.Amarenco P, Lavallée PC, Monteiro Tavares L, Labreuche J, Albers GW, Abboud H, et al. Five-year risk of stroke after TIA or minor ischemic stroke. N Engl J Med. 2018;378:2182–2190. doi: 10.1056/NEJMoa1802712. [DOI] [PubMed] [Google Scholar]
- 12.Purroy F, Montaner J, Molina CA, Delgado P, Ribo M, Alvarez-Sabín J. Patterns and predictors of early risk of recurrence after transient ischemic attack with respect to etiologic subtypes. Stroke. 2007;38:3225–3229. doi: 10.1161/STROKEAHA.107.488833. [DOI] [PubMed] [Google Scholar]
- 13.Mnyusiwalla A, Aviv RI, Symons SP. Radiation dose from multidetector row CT imaging for acute stroke. Neuroradiology. 2009;51:635–640. doi: 10.1007/s00234-009-0543-6. [DOI] [PubMed] [Google Scholar]
- 14.Dittrich R, Akdeniz S, Kloska SP, Fischer T, Ritter MA, Seidensticker P, et al. Low rate of contrast-induced nephropathy after CT perfusion and CT angiography in acute stroke patients. J Neurol. 2007;254:1491–1497. doi: 10.1007/s00415-007-0528-5. [DOI] [PubMed] [Google Scholar]
- 15.Hunt CH, Hartman RP, Hesley GK. Frequency and severity of adverse effects of iodinated and gadolinium contrast materials: retrospective review of 456,930 doses. AJR Am J Roentgenol. 2009;193:1124–1127. doi: 10.2214/AJR.09.2520. [DOI] [PubMed] [Google Scholar]
- 16.North American Symptomatic Carotid Endarterectomy Trial Methods, patient characteristics, and progress. Stroke. 1991;22:711–720. doi: 10.1161/01.str.22.6.711. [DOI] [PubMed] [Google Scholar]
- 17.Hennerici M, Rautenberg W, Sitzer G, Schwartz A. Transcranial doppler ultrasound for the assessment of intracranial arterial flow velocity—part 1. Examination technique and normal values. Surg Neurol. 1987;27:439–448. doi: 10.1016/0090-3019(87)90251-5. [DOI] [PubMed] [Google Scholar]
- 18.Hennerici MG, Kern R, et al. S1-Leitlinie Diagnostik akuter zerebrovaskulärer Erkrankungen. 2017. In: Deutsche Gesellschaft für Neurologie, Hrsg. Leitlinien für Diagnostik und Therapie in der Neurologie. Online: https://www.dgn.org/leitlinien. Accessed 21 Oct 2021.
- 19.Schramm P, Schellinger PD, Fiebach JB, Heiland S, Jansen O, Knauth M, et al. Comparison of CT and CT angiography source images with diffusion-weighted imaging in patients with acute stroke within 6 hours after onset. Stroke. 2002;33:2426–2432. doi: 10.1161/01.str.0000032244.03134.37. [DOI] [PubMed] [Google Scholar]
- 20.Coutts SB, Modi J, Patel SK, Demchuk AM, Goyal M, Hill MD. CT/CT angiography and MRI findings predict recurrent stroke after transient ischemic attack and minor stroke: results of the prospective CATCH study. Stroke. 2012;43:1013–1017. doi: 10.1161/STROKEAHA.111.637421. [DOI] [PubMed] [Google Scholar]
- 21.Lou M, Safdar A, Edlow JA, Caplan L, Kumar S, Schlaug G, et al. Can ABCD2 score predict the need for in-hospital intervention in patients with transient ischemic attacks? Int J Emerg Med. 2010;3:75–80. doi: 10.1007/s12245-010-0176-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Sutton-Tyrrell K, Alcorn HG, Wolfson SK, Kelsey SF, Kuller LH. Predictors of carotid stenosis in older adults with and without isolated systolic hypertension. Stroke. 1993;24:355–361. doi: 10.1161/01.str.24.3.355. [DOI] [PubMed] [Google Scholar]
- 23.Mathiesen EB, Joakimsen O, Bønaa KH. Prevalence of and risk factors associated with carotid artery stenosis: the Tromsø study. Cerebrovasc Dis. 2001;12:44–51. doi: 10.1159/000047680. [DOI] [PubMed] [Google Scholar]
- 24.Blaser T, Hofmann K, Buerger T, Effenberger O, Wallesch C-W, Goertler M. Risk of stroke, transient ischemic attack, and vessel occlusion before endarterectomy in patients with symptomatic severe carotid stenosis. Stroke. 2002;33:1057–1062. doi: 10.1161/01.str.0000013671.70986.39. [DOI] [PubMed] [Google Scholar]
- 25.Hause S, Oldag A, Breja A, Neumann J, Wilcke J, Schreiber S, et al. Acute symptomatic extracranial internal carotid occlusion - natural course and clinical impact. Vasa. 2020;49:31–38. doi: 10.1024/0301-1526/a000826. [DOI] [PubMed] [Google Scholar]
- 26.Johnston SC, Amarenco P, Denison H, Evans SR, Himmelmann A, James S, et al. Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA. N Engl J Med. 2020;383:207–217. doi: 10.1056/NEJMoa1916870. [DOI] [PubMed] [Google Scholar]
- 27.Johnston SC, Easton JD, Farrant M, Barsan W, Conwit RA, Elm JJ, et al. Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA. N Engl J Med. 2018;379:215–225. doi: 10.1056/NEJMoa1800410. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Wang Y, Wang Y, Zhao X, Liu L, Wang D, Wang C, et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med. 2013;369:11–19. doi: 10.1056/NEJMoa1215340. [DOI] [PubMed] [Google Scholar]
- 29.Kvickström P, Lindblom B, Bergström G, Zetterberg M. Amaurosis fugax: risk factors and prevalence of significant carotid stenosis. Clin Ophthalmol. 2016;10:2165–2170. doi: 10.2147/OPTH.S115656. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Smit RL, Baarsma GS, Koudstaal PJ. The source of embolism in amaurosis fugax and retinal artery occlusion. Int Ophthalmol. 1994;18:83–86. doi: 10.1007/bf00919244. [DOI] [PubMed] [Google Scholar]
- 31.Pessin MS, Duncan GW, Mohr JP, Poskanzer DC. Clinical and angiographic features of carotid transient ischemic attacks. N Engl J Med. 1977;296:358–362. doi: 10.1056/NEJM197702172960703. [DOI] [PubMed] [Google Scholar]
- 32.Harrison MJ, Marshall J, Thomas DJ. Relevance of duration of transient ischaemic attacks in carotid territory. Br Med J. 1978;1:1578–1579. doi: 10.1136/bmj.1.6127.1578. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Inzitari D, Eliasziw M, Gates P, Sharpe BL, Chan RK, Meldrum HE, Barnett HJ. The causes and risk of stroke in patients with asymptomatic internal-carotid-artery stenosis. North American symptomatic carotid endarterectomy trial collaborators. N Engl J Med. 2000;342:1693–1700. doi: 10.1056/NEJM200006083422302. [DOI] [PubMed] [Google Scholar]
- 34.Lin HJ, Wolf PA, Kelly-Hayes M, Beiser AS, Kase CS, Benjamin EJ, D'Agostino RB. Stroke severity in atrial fibrillation. Framingham Study. Stroke. 1996;27:1760–1764. doi: 10.1161/01.str.27.10.1760. [DOI] [PubMed] [Google Scholar]
- 35.Yip PK, Jeng JS, Lee TK, Chang YC, Huang ZS, Ng SK, Chen RC. Subtypes of ischemic stroke. A hospital-based stroke registry in Taiwan (SCAN-IV) Stroke. 1997;28:2507–2512. doi: 10.1161/01.str.28.12.2507. [DOI] [PubMed] [Google Scholar]
- 36.Niesten JM, van der Schaaf IC, van Dam L, Vink A, Vos JA, Schonewille WJ, et al. Histopathologic composition of cerebral thrombi of acute stroke patients is correlated with stroke subtype and thrombus attenuation. Plos One. 2014;9:e88882. doi: 10.1371/journal.pone.0088882. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Boeckh-Behrens T, Schubert M, Förschler A, Prothmann S, Kreiser K, Zimmer C, et al. The impact of histological clot composition in embolic stroke. Clin Neuroradiol. 2016;26:189–197. doi: 10.1007/s00062-014-0347-x. [DOI] [PubMed] [Google Scholar]
- 38.Henderson RD, Eliasziw M, Fox AJ, Rothwell PM, Barnett HJ. Angiographically defined collateral circulation and risk of stroke in patients with severe carotid artery stenosis. North American symptomatic carotid endarterectomy trial (NASCET) group. Stroke. 2000;31:128–132. doi: 10.1161/01.str.31.1.128. [DOI] [PubMed] [Google Scholar]
- 39.Purroy F, Jiménez Caballero PE, Gorospe A, Torres MJ, Alvarez-Sabin J, Santamarina E, et al. Recurrent transient ischaemic attack and early risk of stroke: data from the PROMAPA study. J Neurol Neurosurg Psychiatry. 2013;84:596–603. doi: 10.1136/jnnp-2012-304005. [DOI] [PubMed] [Google Scholar]
- 40.Chaturvedi S, Ofner S, Baye F, Myers LJ, Phipps M, Sico JJ, et al. Have clinicians adopted the use of brain MRI for patients with TIA and minor stroke? Neurology. 2017;88:237–244. doi: 10.1212/WNL.0000000000003503. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
All data generated or analysed during this study are included in this published article.